Pharmaceutical composition for external use

Abstract

Provided is a pharmaceutical composition for external use, including: (i) a compound represented by structural formula (2) and/or a salt thereof; and (ii) N-methyl-2-pyrrolidone.

1 . An antimycotic pharmaceutical composition for external antihyperkeratotic use, comprising:
 1) lanoconazole represented by a structural formula (2) below and/or a salt thereof;   2) N-methyl-2-pyrrolidone; and   3) benzyl alcohol and/or diester of a dibasic acid, wherein the diester of the dibasic acid is a diethyl ester or a diisopropyl ester of a dibasic acid having 6-10 carbon atoms:   
       
         
           
           
               
               
           
         
       
     
     
         2 . The antimycotic pharmaceutical composition for external antihyperkeratotic use according to  claim 1 , further comprising an α-hydroxycarboxylic acid and/or a salt thereof. 
     
     
         3 . The antimycotic pharmaceutical composition for external antihyperkeratotic use according to  claim 2 , wherein the α-hydroxycarboxylic acid is lactic acid. 
     
     
         4 . The antimycotic pharmaceutical composition for external antihyperkeratotic use according to  claim 1 , wherein the composition comprises N-methyl-2-pyrrolidone in an amount of 1 to 15% by mass of the composition. 
     
     
         5 . The antimycotic pharmaceutical composition for external antihyperkeratotic use according to  claim 1 , wherein the composition comprises lanoconazole in an amount of 0.5 to 15% by mass of the composition. 
     
     
         6 . The antimycotic pharmaceutical composition for external antihyperkeratotic use according to  claim 1 , further comprising 50-90% by mass of ethanol. 
     
     
         7 . The antimycotic pharmaceutical composition for external antihyperkeratotic use according to  claim 1 , wherein the pharmaceutical composition is a lotion. 
     
     
         8 . A method of treating a mycotic disease comprising externally administering the composition of  claim 1  to an individual in need of treatment. 
     
     
         9 . The method according to  claim 8 , wherein the mycotic disease is foot trichophytosis, trichophytosis corporis, trichophytosis on a hard keratin portion, or trichophytosis on a hyperkeratotic portion. 
     
     
         10 . The method according to  claim 8 , wherein the mycotic disease is onychomycosis. 
     
     
         11 . The method according to  claim 8 , wherein the mycotic disease is a mycotic disease of a nail. 
     
     
         12 . A method according to  claim 8 , wherein the mycotic disease is dermatomycosis. 
     
     
         13 . The antimycotic pharmaceutical composition of  claim 1  for external antihyperkeratotic use, wherein the diester of the dibasic acid is a diethyl ester or a diisopropyl ester of adipic acid or sebacic acid. 
     
     
         14 . The antimycotic pharmaceutical composition of  claim 1  for external antihyperkeratotic use, wherein the composition comprises benzyl alcohol in an amount of 1 to 15% by mass of the composition. 
     
     
         15 . The antimycotic pharmaceutical composition of  claim 1  for external antihyperkeratotic use, wherein the composition comprises the diester of the dibasic acid which is a diethyl ester or a diisopropyl ester of a dibasic acid having 6-10 carbon atoms in an amount of 1 to 30% by mass of the composition.